Wanbury Limited (WANBURY)
₹192.36 +3.25% last close, 16 Oct
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Wanbury's revenue was ₹166 Cr (+1.5% year on year, +0.4% on the previous quarter), and net profit ₹3.2 Cr (-76.0% year on year); the operating margin was 9.8%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹166 | +1.5% | +0.4% |
| Operating profit | ₹16.2 | -33.6% | -45.9% |
| Net profit | ₹3.2 | -76.0% | -85.3% |
| EPS (₹) | 0.93 | -77.4% | -85.0% |
| Operating margin | 9.8% | — | — |
WANBURY delivery percentage and bulk deals
NSE end-of-day data for
On Fri, 16 Oct 2026, 36.54% of the WANBURY shares traded on NSE were taken to delivery, against the stock's own 20-session average of 47.62%. The price rose 3.25% on unusually low delivery, so more of the move than usual was intraday trading. 1 bulk or block deal was reported in WANBURY in the last 60 days: ₹4 Cr sold, none bought.
Delivery in the last 5 sessions: 32.4% · 54.5% · 59.7% · 41.2% · 36.5%
| Date | Side | Counterparty | Value | Price | Quantity | Type |
|---|---|---|---|---|---|---|
| 6 Oct | Sell | Dhunseri Ventures Limited | ₹3.94 Cr | ₹199.95 | 197,146 | Bulk |
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Wanbury announced receipt of 9 'No DMF Deficiency' letters from the USFDA for Metformin HCl, along with clearances for Paroxetine and Diphenhydramine HCl during July-August 2026. The company also expanded its commercial footprint with a new Metformin DC business in Saudi Arabia (~Rs 10 crore annual potential) and a 2-year tender won by its Mexican customer (~Rs 15 crore per annum). Combined, these new business additions represent ~Rs 25 crore in annual revenue potential, or roughly 4% of TTM revenue (Rs 629 crore). Furthermore, Wanbury plans regulatory filings next quarter for three new APIs: Quetiapine Fumarate, Sitagliptin, and Empagliflozin.
- Received 9 'No DMF Deficiency' letters from USFDA for Metformin HCl during July–August 2026
- Commercialised Metformin DC business in Saudi Arabia with ~Rs 10 crore annual revenue potential
- Customer in Mexico secured a 2-year Metformin supply tender valued at ~Rs 15 crore per annum
- Filing regulatory submissions next quarter for 3 pipeline APIs: Quetiapine Fumarate, Sitagliptin, and Empagliflozin
Wanbury Limited's subsidiary, Wanbury Skin Health Limited, has launched its 'berrysoft baby' product portfolio, marking its strategic foray into the paediatric dermatology segment. The company has secured GST registrations in 5 states (including Maharashtra, Delhi, and Karnataka) with 3 more pending, alongside CFA Drug Licenses across 4 cities (Mumbai, Jaipur, Patna, and Ambala). The initial rollout covers four products (Gentle Bathing Bar, Gentle Body Wash, Foam Shampoo, and Syndet Handwash), with three additional products in the pipeline. Wanbury aims to cross-sell to its existing paediatrician network previously tapped for its cold and cough product lines.
- Launches 'berrysoft baby' range marking entry into paediatric dermatology segment
- Secured GST registration across 5 states with 3 more in the pipeline
- Received CFA Drug Licenses across 4 cities with 4 more in the pipeline
- Initial rollout of 4 products with 3 additional skincare formulations in the pipeline
Wanbury Limited announced that its subsidiary, Wanbury Skin Health Limited, has launched its 'berrysoft baby' skincare product range across multiple states. The company secured GST registrations in 5 states (including Maharashtra, Delhi, and Karnataka) with 3 more in the pipeline, alongside CFA Drug Licenses across 4 locations. The initial portfolio includes 4 products (bathing bar, body wash, shampoo, handwash) with 3 more under development, targeting paediatrician cross-selling to leverage Wanbury's existing formulations reach. While revenue potential is undisclosed, this marks Wanbury's diversification beyond APIs into branded consumer and paediatric dermatology.
- Launched 4 products in the berrysoft baby range: Gentle Bathing Bar, Gentle Body Wash, Foam Shampoo, and Syndet Handwash
- 3 additional products in pipeline: Moisturising Lotion, Diaper Rash Cream, and Moisturising Cream
- Secured GST registration in 5 states (including Maharashtra, Delhi, Karnataka) with 3 more in pipeline
- Obtained CFA Drug Licenses in 4 locations (Mumbai, Jaipur, Patna, Ambala) with 4 more in pipeline
Wanbury Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by Registrar and Share Transfer Agent Purva Sharegistry (India) Pvt. Ltd., covers the quarter ended 30th September, 2026. It confirms that share certificates received for dematerialisation during the period were properly verified, listed on exchanges, and mutilated or cancelled. This is a standard quarterly administrative filing with no material business impact.
- Filing submitted under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018
- Compliance period covers the quarter ended 30th September, 2026
- Certificate issued by RTA Purva Sharegistry (India) Pvt. Ltd. dated 01st October, 2026
- Filing executed and submitted to BSE and NSE on 09th October, 2026
Wanbury Limited announced multiple regulatory milestones, including filing a new Drug Master File (DMF) in South Africa for Tramadol HCl API and DMFs in the Philippines and Singapore for Metformin HCl API. Additionally, EDQM approved added Key Starting Materials (KSM) vendors for Paroxetine HCl API to ensure supply continuity. Australia's Therapeutic Goods Administration (TGA) has also accepted Wanbury's compliance report, clearing the way to continue API supplies to Australia. These filings strengthen the company's international compliance posture across 4 distinct regions.
- Filed new Drug Master File (DMF) in South Africa for Tramadol HCl API
- Filed DMFs in 2 Southeast Asian markets—Philippines and Singapore—for Metformin HCl API
- Received EDQM approval for additional Key Starting Materials (KSM) vendors for Paroxetine HCl
- Secured compliance clearance from Australia's TGA following inspectional observations
Wanbury Limited announced that shareholders approved key resolutions at the 38th AGM held on September 24, 2026. The company approved the re-appointment and continuation of Mr. Mohan Kumar Rayana as Whole-time Director beyond the age of 70, for a 5-year tenure effective from August 21, 2026, to August 20, 2031. Additionally, shareholders approved the appointment and remuneration of M/s. ABK & Associates as Cost Auditor for FY 2026-2027.
- Re-appointment of Whole-time Director Mohan Kumar Rayana approved for a 5-year term from August 21, 2026, to August 20, 2031
- Approval granted for Director's continuation beyond the age of 70 years
- Appointment and remuneration of Cost Auditor M/s. ABK & Associates approved for FY 2026-2027
- 38th Annual General Meeting concluded on September 24, 2026, between 11:30 a.m. and 12:35 p.m.
Wanbury Limited held its 38th Annual General Meeting on September 24, 2026, via video conferencing. Shareholders approved all four proposed resolutions with the requisite majority, as confirmed by the Scrutinizer's report. Key approvals include the adoption of FY26 audited financial statements, the re-appointment of Mr. K. Chandran retiring by rotation, and a special resolution re-appointing Mr. Mohan Kumar Rayana as Whole-time Director beyond age 70. Detailed voting tallies are scheduled to be uploaded to the company's website within 48 hours.
- 38th Annual General Meeting conducted on September 24, 2026
- All 4 ordinary and special resolutions approved with requisite majority
- Special resolution passed for continuation of Whole-time Director Mohan Kumar Rayana beyond 70 years of age
- Meeting concluded within 65 minutes (commenced at 11:30 AM and ended at 12:35 PM)
Wanbury Limited has announced that its 38th Annual General Meeting (AGM) will be held on Thursday, September 24, 2026, at 11:30 AM via video conferencing. Pursuant to Section 91 of the Companies Act, 2013, the Register of Members and Share Transfer Books will remain closed from September 18, 2026, to September 24, 2026 (both days inclusive). This is a routine administrative compliance filing with no impact on company operations or financials.
- 38th Annual General Meeting scheduled for September 24, 2026, at 11:30 AM
- Book closure period set from September 18, 2026, to September 24, 2026 (both days inclusive)
- AGM to be conducted via Video Conferencing (VC) / Other Audio Visual Means (OAVM)
Wanbury Limited has issued the notice for its 38th Annual General Meeting scheduled for September 24, 2026, via video conferencing, alongside the dispatch of its FY26 Annual Report. Key agenda items include the adoption of FY26 financial statements and ratification of Rs 4,00,000 cost auditor remuneration for FY27. Shareholders will also vote on a special resolution to re-appoint Mr. Mohan Kumar Rayana as Whole-time Director for a 5-year tenure extending up to August 20, 2031.
- 38th Annual General Meeting scheduled for Thursday, September 24, 2026, at 11:30 A.M. via VC/OAVM
- Special resolution proposed for the re-appointment of Whole-time Director Mohan Kumar Rayana for a 5-year term from August 21, 2026 to August 20, 2031
- Approval sought for cost audit remuneration of Rs 4,00,000 payable to M/s. ABK & Associates for FY 2026-2027
- Ordinary business includes adoption of FY26 audited financial statements and director retirement by rotation of Mr. K. Chandran
Wanbury Limited has received approval from the European Directorate for the Quality of Medicines (EDQM) for its new Rivaroxaban API, enabling sales in the EU and other CEP-accepting markets. Additionally, the company secured USFDA DMF clearances for Paroxetine HCl and Metformin HCl. These approvals are critical as approximately 65% of Wanbury's export revenue is dependent on maintaining USFDA and EDQM compliance. The clearances support the company's ongoing ANDA reviews for multiple customers, potentially driving volume growth in regulated markets.
- Received EDQM approval for new product Rivaroxaban API for European markets
- Obtained USFDA DMF clearances for Paroxetine HCl and Metformin HCl
- Regulatory compliance protects the 65% of export revenue derived from stringent markets
- Supports the company's global leadership in Metformin, where it has 8,500 tons/year capacity
- Clearances coincide with ongoing ANDA reviews for multiple international customers
Wanbury reported a weak Q1 FY27 with PAT declining 76% YoY to ₹3.2 Cr, primarily due to a 517 bps contraction in EBITDA margins caused by rising solvent and crude-linked input costs. Despite the earnings miss, the company achieved a major structural milestone by refinancing ₹205 Cr of debt, reducing interest rates from 12.5% to sub-10% effective July 2026. This refinancing also resulted in the release of pledges on 40.65% of the company's total equity, significantly improving the promoter's holding profile. Regulatory progress remained strong with successful inspections by Australian and Korean agencies.
- PAT dropped 76% YoY to ₹3.2 Cr from ₹13.5 Cr, with EPS falling to ₹0.93 from ₹4.12.
- EBITDA margins contracted to 10.0% from 15.2% YoY due to West Asia crisis-linked raw material inflation.
- Refinanced ₹205 Cr debt with Axis Finance and Poonawalla Fincorp, lowering borrowing costs by over 250 bps.
- Released pledge on 1.42 Cr shares, representing 40.65% of total equity and 94.51% of promoter holding.
- Patalganga facility cleared Korean MFDS inspection with zero observations; Tanuku site cleared Australian TGA.
Wanbury Limited has allotted 27,530 equity shares to employees under its 2016 ESOP plan at an exercise price of Rs 10 per share. This results in a negligible equity dilution of approximately 0.08% of the total paid-up capital. Additionally, the Board has re-appointed Mr. Mohan Kumar Rayana as Whole-time Director for a five-year term effective August 21, 2026, ensuring leadership continuity. The company also approved its unaudited financial results for the quarter ended June 30, 2026.
- Allotment of 27,530 equity shares of face value Rs 10 each following the exercise of vested options.
- Total money realized from the exercise of options amounts to Rs 2,75,300.
- Paid-up share capital increased from 3,49,39,398 to 3,49,66,928 equity shares.
- Re-appointment of Mr. Mohan Kumar Rayana as Whole-time Director for a 5-year term starting August 21, 2026.
- The board meeting for these approvals concluded at 7:30 P.M. on August 11, 2026.
Wanbury Limited reported a weak Q1 FY27 with PAT falling to ₹3.24 Cr from ₹13.49 Cr YoY. However, the company executed a major financial restructuring, refinancing ₹205 Cr of high-cost debt through NBFCs, which led to the release of 85.20 lakh pledged promoter shares on July 7, 2026. Operationally, the company cleared TGA Australia and MFDS-Korea inspections with zero observations. The Board also re-appointed Mohan Kumar Rayana as Whole-time Director for a five-year term starting August 21, 2026.
- Q1 FY27 PAT stood at ₹3.24 Cr, a significant decline from ₹13.49 Cr in the year-ago period.
- Refinanced ₹205 Cr of high-cost debt (representing ~32% of TTM revenue) to improve interest coverage and fund capex.
- Released 85,20,330 pledged promoter shares following the repayment of existing high-cost borrowings.
- Cleared regulatory inspections from TGA Australia and MFDS-Korea with zero observations at two API facilities.
- Re-appointed Mohan Kumar Rayana as Whole-time Director for a 5-year term effective August 21, 2026.
Wanbury Limited's board approved the unaudited financial results for the quarter ended June 30, 2026. The company also allotted 27,530 equity shares to employees under its 2016 ESOP plan at an exercise price of Rs 10 per share, resulting in a negligible equity dilution of approximately 0.08%. Furthermore, Mr. Mohan Kumar Rayana was re-appointed as Whole-time Director for a five-year term effective August 21, 2026, ensuring leadership continuity. The total money realized from the ESOP exercise was Rs 2.75 lakh.
- Allotment of 27,530 equity shares of Rs 10 face value following ESOP exercise
- Paid-up share capital increased to Rs 34.97 Cr from Rs 34.94 Cr
- Re-appointment of Mr. Mohan Kumar Rayana as Whole-time Director for a 5-year term
- Total money realized from the ESOP exercise amounted to Rs 2,75,300
- Board meeting concluded after 4 hours of deliberation (3:30 PM to 7:30 PM)
Wanbury Limited has received a 'No DMF deficiency letter' from the USFDA for multiple Abbreviated New Drug Applications (ANDAs) that utilize its Metformin HCl API. This is a critical regulatory milestone as the company is the world's largest manufacturer of Metformin with a capacity of 8,500 tons per year. Maintaining USFDA compliance is vital for Wanbury, as approximately 65% of its export revenue is dependent on adherence to stringent regulatory standards. The company also confirmed expansion into the South Korean market with a new DMF filing for another API.
- Received 'No DMF deficiency letter' from USFDA for multiple ANDAs using Metformin HCl API
- Metformin capacity stands at 8,500 tons per year, making Wanbury the largest global manufacturer
- Regulatory compliance protects 65% of export revenue which relies on USFDA/EDQM approved sites
- Expanded business footprint into South Korea by filing a DMF for an additional API
- Maintains cumulative reactor capacity of 386 KL across two USFDA-approved facilities
Financial Performance
Revenue Growth by Segment
API revenue grew 8.2% YoY to INR 277 Cr in H1 FY26, while Formulations revenue grew 17.6% YoY to INR 40 Cr in H1 FY26. Total revenue for H1 FY26 was INR 323.2 Cr, up 10.57% YoY from INR 292.3 Cr.
Geographic Revenue Split
80% of revenue is derived from Exports, with 65% of that comprising regulated markets. Domestic sales contribute the remaining 20% of the total revenue mix.
Profitability Margins
Gross Margin improved from 39% in FY23 to 56.11% in H1 FY26. PAT Margin turned positive from -2.08% in FY23 to 5.28% in FY24 and reached 8.87% in H1 FY26 due to operational efficiencies and debt restructuring.
EBITDA Margin
EBITDA Margin was 15.7% in H1 FY26, a significant improvement from 4.7% in FY23. EBITDA scaled up ~3X between FY23 and FY25 through de-bottlenecking and production scale-up.
Capital Expenditure
Planned Capex of INR 64 Cr in FY25 (INR 38 Cr for new products, INR 14 Cr for de-bottlenecking) and INR 63 Cr in FY26 (INR 45 Cr for a new production block and clean rooms).
Credit Rating & Borrowing
Credit rating is IVR C+/Negative (Issuer Not Cooperating) as of October 2024. Borrowing costs were reduced from 22.5% to 12.5% effective March 1, 2025, following the exit of high-cost private financial agreements.
Operational Drivers
Raw Materials
Key raw materials are chemical precursors for Metformin and Sertraline; COGS represented 44% of revenue in H1 FY26 (INR 142.4 Cr).
Import Sources
Not specifically disclosed in available documents, though the company exports to 50+ countries and operates in global API markets.
Capacity Expansion
Metformin capacity is 8,500 tons per year (largest manufacturer globally). Capacity for Metformin and Sertraline increased by 25% and 20% respectively over the last 3 years through de-bottlenecking.
Raw Material Costs
COGS as a % of revenue decreased from 60.7% in FY23 to 44% in H1 FY26, reflecting efficient procurement practices and technical savings.
Manufacturing Efficiency
Capacity ramp-up achieved through de-bottlenecking projects; cumulative reactor capacity stands at 386 KL across 2 USFDA approved facilities.
Strategic Growth
Expected Growth Rate
10.60%
Growth Strategy
Growth will be driven by launching an Anaesthetic in Q4 FY26 and a pipeline of 4 new molecules commercialized each year starting next FY. Strategic focus includes brownfield expansion, entering China/Brazil markets, and scaling top brands in Formulations to achieve sustainable profitability by FY27.
Products & Services
API products including Metformin, Sertraline, and Anaesthetics. Branded Formulations include C Pink and Wanbury C RED.
Brand Portfolio
C Pink, Wanbury C RED.
New Products/Services
Launch of an Anaesthetic in Q4 FY26 and 4 new molecules per year starting FY27; Formulations business achieved financial break-even in H1 FY26.
Market Expansion
Expanding regulatory footprints in China (expecting approval for 1 more API) and Brazil (ANVISA approved in Dec 2024).
Market Share & Ranking
Largest manufacturer of Metformin globally with 8,500 tons/year; globally significant market share in Sertraline.
Strategic Alliances
Historical strategic alliance with Wyckoff Chemicals (US) for API manufacturing.
External Factors
Industry Trends
The industry is shifting toward chronic therapies; Wanbury has aligned 100% of its API portfolio to chronic segments. The company is positioned to benefit from the 10.6% growth trend seen in H1 FY26.
Competitive Landscape
Wanbury is a mid-size pharma company ranked among the Top 50 in India (ORG-IMS), competing in the global API and domestic branded formulation markets.
Competitive Moat
Moat is built on being the world's largest Metformin producer and having long-standing USFDA approvals (since 2000). This cost leadership and regulatory track record are highly sustainable due to high entry barriers in regulated API markets.
Macro Economic Sensitivity
Sensitivity to global pharmaceutical demand and regulatory changes in the US and Europe, which govern 65% of export top-line.
Consumer Behavior
Increased demand for chronic disease management (Diabetes/Metformin) is driving long-term volume growth.
Geopolitical Risks
Exposure to trade barriers in regulated markets; mitigating this by expanding into China and Brazil.
Regulatory & Governance
Industry Regulations
Subject to USFDA (last inspection 2024, zero 483), EDQM (Europe), ANVISA (Brazil), and WHO GMP regulations. Compliance is mandatory for 80% of revenue derived from exports.
Environmental Compliance
Maintains Environment, Health & Safety (EHS) standards as part of corporate profile; specific costs not disclosed.
Risk Analysis
Key Uncertainties
Regulatory risk (potential impact on 65% of exports) and high debt-to-equity levels, although gearing improved from 4.96x in FY24 to 3.25x in FY25.
Geographic Concentration Risk
80% revenue concentration in Export markets, making the company sensitive to international trade policies.
Third Party Dependencies
Low dependency on single suppliers or customers as per management commentary.
Technology Obsolescence Risk
Digital transformation status includes 'GPS reporting' to improve field force efficiency in the Formulations business.
Credit & Counterparty Risk
Trade payables stood at INR 112.53 Cr in H1 FY26; the company has exited high-cost private financial agreements to improve credit standing.
